Larvol Delta - aTyr-Pharma-Announces-Second-Positive-DSMB-Review-for-Efzotimod-in-Phase-3-EFZOFIT-Study-in-Pulmonary-Sarcoidosis

Stalaris (efzofitimod) - aTyr Pharma, Kyorin

https://www.globenewswire.com/news-release/2024/10/08/2959628/0/en/aTyr-Pharma-s-Lead-Therapeutic-Candidate-Efzofitimod-for-Pulmonary-Sarcoidosis-to-be-Featured-in-Best-of-CHEST-Journals-at-CHEST-2024-Annual-Meeting.html

Oct 8, 2024

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next